261.00
0.69%
-1.655
前日終値:
$262.65
開ける:
$260.83
24時間の取引高:
747.90K
Relative Volume:
0.26
時価総額:
$139.35B
収益:
$32.53B
当期純損益:
$4.23B
株価収益率:
18.55
EPS:
14.07
ネットキャッシュフロー:
$6.28B
1週間 パフォーマンス:
-1.19%
1か月 パフォーマンス:
-7.78%
6か月 パフォーマンス:
-16.51%
1年 パフォーマンス:
-9.43%
Amgen Inc Stock (AMGN) Company Profile
AMGN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
261.03 | 139.35B | 32.53B | 4.23B | 6.28B | 7.81 |
LLY
Lilly Eli Co
|
776.00 | 693.98B | 40.86B | 8.37B | -2.28B | 9.25 |
NVO
Novo Nordisk Adr
|
86.29 | 383.15B | 39.36B | 13.79B | 9.83B | 3.086 |
JNJ
Johnson Johnson
|
143.58 | 345.38B | 87.70B | 14.68B | 19.03B | 6.05 |
ABBV
Abbvie Inc
|
176.66 | 310.86B | 55.53B | 5.12B | 15.62B | 2.88 |
MRK
Merck Co Inc
|
98.75 | 249.49B | 63.17B | 12.15B | 14.84B | 4.77 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-10 | 再開されました | BofA Securities | Underperform |
2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
2024-11-14 | 開始されました | Citigroup | Neutral |
2024-10-17 | 開始されました | Bernstein | Outperform |
2024-10-14 | ダウングレード | Truist | Buy → Hold |
2024-09-27 | 開始されました | Cantor Fitzgerald | Overweight |
2024-08-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2024-05-03 | アップグレード | Barclays | Underweight → Equal Weight |
2024-05-03 | アップグレード | William Blair | Mkt Perform → Outperform |
2024-03-28 | 再開されました | Raymond James | Mkt Perform |
2024-02-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2023-12-21 | アップグレード | Daiwa Securities | Neutral → Buy |
2023-12-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2023-12-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2023-11-09 | 開始されました | Deutsche Bank | Hold |
2023-11-02 | アップグレード | Truist | Hold → Buy |
2023-10-20 | 再開されました | JP Morgan | Neutral |
2023-10-17 | 再開されました | Morgan Stanley | Equal-Weight |
2023-10-11 | 再開されました | BofA Securities | Neutral |
2023-09-06 | 開始されました | HSBC Securities | Buy |
2023-04-24 | 繰り返されました | Oppenheimer | Outperform |
2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2023-02-13 | 繰り返されました | Truist | Buy |
2022-11-18 | 開始されました | Credit Suisse | Underperform |
2022-10-31 | ダウングレード | Barclays | Equal Weight → Underweight |
2022-10-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
2022-02-09 | 繰り返されました | Barclays | Equal Weight |
2022-02-09 | 繰り返されました | Jefferies | Buy |
2022-02-09 | 繰り返されました | Morgan Stanley | Equal-Weight |
2022-02-09 | 繰り返されました | Oppenheimer | Outperform |
2022-02-09 | 繰り返されました | Wells Fargo | Equal Weight |
2022-01-05 | ダウングレード | BofA Securities | Buy → Neutral |
2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
2021-12-06 | 開始されました | Goldman | Buy |
2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
2021-09-23 | ダウングレード | Daiwa Securities | Outperform → Neutral |
2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-12-29 | 開始されました | Daiwa Securities | Buy |
2020-10-28 | 開始されました | UBS | Neutral |
2020-10-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
2020-10-12 | アップグレード | Truist | Hold → Buy |
2020-10-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
2020-10-09 | ダウングレード | Truist | Buy → Hold |
2020-10-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2020-04-15 | 再開されました | Guggenheim | Neutral |
2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
2020-03-30 | アップグレード | Raymond James | Mkt Perform → Outperform |
2020-03-05 | アップグレード | BofA/Merrill | Neutral → Buy |
2020-02-27 | 開始されました | Barclays | Equal Weight |
2020-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
2020-01-21 | アップグレード | Evercore ISI | In-line → Outperform |
2019-12-24 | 開始されました | Raymond James | Mkt Perform |
2019-12-17 | 再開されました | Morgan Stanley | Overweight |
2019-11-12 | 開始されました | SunTrust | Buy |
2019-11-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
2019-10-17 | 再開されました | BofA/Merrill | Neutral |
2019-08-19 | ダウングレード | Mizuho | Buy → Neutral |
2019-05-23 | アップグレード | Citigroup | Neutral → Buy |
すべてを表示
Amgen Inc (AMGN) 最新ニュース
Amgen Plans To Expand N.C. Campus - Los Angeles Business Journal
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Amgen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Amgen buys 22 acres near its New Albany facilityColumbus Business First - The Business Journals
Amgen Inc. stock rises Tuesday, still underperforms market - MarketWatch
Here's Why Amgen (AMGN) Gained But Lagged the Market Today - Yahoo Finance
Amgen Inc. stock rises Monday, still underperforms market - MarketWatch
Burkitt Lymphoma Global Clinical Trials Review 2024: Clinical Trials by Region, Country, Trial Status, Trial Phase, Sponsor Type and End Point Status - GlobeNewswire Inc.
Amgen, Lilly Sue HHS Over Clinics in Drug Discount Program - Bloomberg Law
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - MSN
Cell Therapy Market Overall Study Report 2024-2031 | Amgen Inc., - openPR
Novo obesity data positive for Eli Lilly and Amgen, says UBS - Yahoo Finance
Amgen - Contract Pharma
Amgen Inc. stock rises Friday, still underperforms market - MarketWatch
What's Going On With Amgen Stock On Friday? - Benzinga
Amgen (AMGN) Rises Over 3% Amid Novo Nordisk Trial Results - GuruFocus.com
Amgen (NASDAQ:AMGN) Shares Gap UpTime to Buy? - MarketBeat
Principal Financial Group Inc. Increases Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
[Amgen Inc. v. Sanofi] Oral Argument - C-SPAN
Amgen (NASDAQ:AMGN) Reaches New 1-Year LowTime to Sell? - MarketBeat
Amgen stock touches 52-week low at $257.77 amid market shifts By Investing.com - Investing.com South Africa
Amgen stock touches 52-week low at $257.77 amid market shifts - Investing.com Australia
Why Is Amgen Inc. (AMGN) Among the Best Dividend Stocks to Invest In? - Insider Monkey
Herceptin Biosimilar Market Future Business Opportunities - openPR
Amgen's SWOT analysis: stock poised for growth amid obesity market potential - Investing.com
Amgen Hit With $50M Infringement Verdict Over Leukemia Drug - Law360
Amgen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit - Reuters.com
Amgen Owes Lindis $50 Million Patent Royalty Over Blincyto (1) - Bloomberg Law
Amgen (NASDAQ:AMGN) Stock Rating Lowered by StockNews.com - MarketBeat
Biologics Market to See Booming Growth 2024-2031 | AbbVie Inc., - openPR
Amgen (AMGN) Stock Moves -0.21%: What You Should Know - Yahoo Finance
Amgen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Is Amgen Inc. (AMGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
KRAS Inhibitors Market Top Companies StudyAmgen, Boehringer - openPR
Viridian taking on Amgen in TED market - BioCentury
Viridian Continues Building Case For Veligrotug In TED - Citeline News & Insights
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen - Yahoo! Voices
Amgen's SWOT analysis: obesity program drives stock outlook - Investing.com
How Much Would It Take To Earn $100 A Month From Amgen Stock - Yahoo Finance
Amgen's (NASDAQ:AMGN) investors will be pleased with their favorable 34% return over the last three years - Simply Wall St
Amgen's (NASDAQ:AMGN) Dividend Will Be Increased To $2.38 - Simply Wall St
Amgen Inc. (NASDAQ:AMGN) Shares Bought by Franklin Resources Inc. - MarketBeat
World Investment Advisors LLC Raises Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dow's 112-point fall led by losses in NVIDIA Corp., Amgen shares - MarketWatch
Amgen to build $1B North Carolina pharmaceutical plant - Manufacturing Dive
Asset Advisors Investment Management LLC Boosts Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Synovus Financial Corp - MarketBeat
Virtu Financial LLC Takes Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc (AMGN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):